TMCnet News

Cerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical Center
[October 19, 2017]

Cerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical Center


Cerveau Technologies Inc. today announced an agreement with Columbia University Medical Center in New York, New York to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.

As part of the agreement, Cerveau will supply the [18F]MK-6240 needed for the initiatives.

According to Dr. William Kreisl from CUMC "PET imaging with [18F]MK-6240 promises to be an excellent complement to the ongoing research at Columbia University. We look forward to using MK-6240 to measure the spread of tau pathology as an addition to our ongoing clinical PET studies. This exciting new research tool has enormous potential to further our investigations into the causes of Alzheimer's disease and our efforts to discover new treatments for this disorder."

"Cerveau is focused on providing information and technologies to researchers and clinicians to improve brain health," said Rick Hiatt, President and CEO of Cerveau Technologies, Inc., "We are excited by the opportunity to work with CUMC and the pharmaceutical industry in providing access to this novel imaging agent to the broader scientific community.

About Columbia University Medical Center

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman Schol of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. The campus that Columbia University Medical Center shares with its hospital partner, NewYork-Presbyterian, is now called the Columbia University Irving Medical Center. For more information, visit cumc.columbia.edu or columbiadoctors.org.



The Taub Institute for Research on Alzheimer's Disease and the Aging Brain at Columbia University Medical Center and NewYork-Presbyterian Hospital brings together researchers and clinicians across disciplines to uncover the causes of Alzheimer's, Parkinson's, and other age-related brain diseases, and to discover ways to treat, prevent, and ultimately cure these diseases. In collaboration with the Departments of Pathology & Cell Biology and Neurology, research in the Taub Institute integrates genetic analysis, molecular and cellular studies, and clinical investigation to better understand complex neurodegenerative disorders. Funding for the Taub Institute's Alzheimer's Disease Research Center is provided by the NIH National Institute on Aging. In 2016, the Taub Institute was designated as a Center of Excellence for Alzheimer's Disease by the New York State Department of Health. For more information, visit The Taub Institute at http://www.cumc.columbia.edu/dept/taub/.

About Cerveau Technologies, Inc.


Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.


[ Back To TMCnet.com's Homepage ]